Kidney Week

This is an exciting time for the kidney community. With breakthrough science and technology providing challenges and opportunities for real-world care, this expert panel focuses on various aspects of implementation science, health policy, health economics, and the future of kidney care. Note: Continuing education credits are not...

ASN Business Meeting

ADPKD is the most common inherited kidney disease. This session covers the latest advances in precision medicine for ADPKD. Experts discuss challenges in molecular diagnosis, new in vitro disease models, experimental therapeutics, and the latest treatment guidelines.

Antibody-mediated glomerular diseases are an important cause of kidney disease, particularly in young adults. Over the past decade, novel treatments have evolved to target pathogenic antibody production, offering new ways to achieve disease control and, in some cases, long-term drug-free remission. This session reviews the fundamen...

This clinicopathologic session focuses on the diagnosis and management of real, de-identified patients with glomerular diseases. Each case is presented by a nephrology professional and a nephropathology professional to a glomerular disease expert, who guides the audience through the case's diagnostic and management strategy. The in...

Managing patients with failing kidney allografts poses challenges, including timing of dialysis reinitiation, immunosuppression management, and relisting. KDIGO guidelines include recommendations for post-transplant anemia and the use of novel therapies. The BK virus (BKV) remains a challenge, and recent clinical trial data provide...

Testing for APOL1 kidney risk variants is now available through many research and clinical laboratories. This session explores the indications for testing for risk alleles; consent for genetic testing; and the medical, ethical, legal, and social implications of genetic testing.

This clinical practice session reviews differences in molecules that target aldosterone inhibition, as well as various incretin therapies for diabetic kidney disease (DKD). Approaches to guideline-directed medical therapies are reviewed, and a case-based discussion presents specific scenarios to clarify implementation challenges.

Artificial intelligence (AI) is increasingly integrated into kidney care, prompting concern and curiosity about whether it will support or replace nephrology professionals. This session provides clinicians with a clear, nontechnical foundation in how AI works, followed by an overview of its current uses in nephrology and its limita...

Opportunities to evaluate interventions for kidney diseases are increasing as new treatments are identified and the capacity to more efficiently generate rigorous clinical trial evidence is growing. This session reviews newer approaches to conducting clinical trials in nephrology. Experts use examples from recently completed or ong...

This session brings together emerging concepts and practical challenges in measuring kidney function in hospitalized patients, moving beyond the historic reliance on serum creatinine alone. The session highlights cutting-edge tools, emerging metrics, and the promise of tubular function markers to refine inpatient assessment. Expert...